Uses
PF-4878691 (3M-852A) is an orally active TLR7 agonist. PF-4878691 has the innate immune response activity, antiviral efficacy against HCV, and can be used for the research of cancer[1][2].
References
[1] Fidock MD, et al. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011 Jun;89(6):821-9. DOI:
10.1038/clpt.2011.60[2] Birmachu W, et al. Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists [J]. BMC immunology, 2007, 8: 1-19.
[3] Horscroft NJ, et al. Antiviral applications of Toll-like receptor agonists. J Antimicrob Chemother. 2012 Apr;67(4):789-801. DOI:
10.1093/jac/dkr588